Medical Oncology, Bayer Consumer Care AG, Basel, Switzerland
Author in the following contributions
- Use of bone health agents (BHAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 after abiraterone: An interim review of REASSURE
- Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)